"Pfizer" tablets fail to prevent infection of contacts with a person infected with the Corona virus

Pfizer Inc said Friday that a large trial concluded that its anti-Covid-19 tablets, Baxolvid, had not been shown to be effective in preventing people living with someone with the virus from getting sick.

The experiment included three thousand adults who were in contact with a person with symptoms of Covid-19 in the same house, and tests confirmed that he had it.

These subjects were given either baxlovid for five or ten days or a placebo.

Those who took the drug for five days had a 32 percent lower risk of infection than the placebo group.

That rose to 37 percent after taking baxlovid for ten days.

But these results were not statistically significant and so may have been due to chance.

Pfizer said the trial's safety data was consistent with previous studies that showed the tablets were 90 percent effective in preventing hospital admissions for high-risk patients when taken for five days soon after symptoms began.

“Although we are disappointed with the outcome of this particular study, these findings do not affect the robust efficacy and safety data we observed in our previous trial of treating COVID-19 patients... We are pleased to see increased use of baxlovid among these individuals,” Pfizer CEO Albert Burla said in a statement. population worldwide.

Follow our latest local and sports news and the latest political and economic developments via Google news